In this session, Dr. Anderson will discuss how the evolution of cancer patient assessment has evolved in the past 30 years. How to look at the big picture of the patient case as well as the detail and how knowing what “phase” the cancer is in can help the clinician appropriately focus time and resources.
We will discuss GI specific microbiome and cancer connections as well as specific cancer therapies. In this session Dr. Anderson will relate his experience and his review of the current data regarding the approach to GI cancers and their relationship to the microbiome. GI specific therapies and implementation will be discussed.
#70 Toxins, Immune Function, and Cancer CE 2.0 Total | 1.o of which are Pharm Risk factors for cancer and proposed mechanisms: Metal toxins Chemical toxins Mycotoxins Testing and assessment: Therapeutic Strategies: In the preventive setting In the “secondary prevention” setting treating after cancer care to prevent recurrence Got a question? Head to the forum! …
#64 PHARM Part-20 Repurposed Drugs in Oncology CE 1.5 Total | 1.5 of which are Pharm Antibiotics, Anti-parasite and other drugs in cancer care? These seem to be making a lot of waves in oncology these days. Dr. Anderson will outline the data for and use of the primary off-label drug strategies as well as …
#66 Controversies in Oncology CE 2.0 Total | 1.5 of which are Pharm Controversies (or maybe not) in Integrative Oncology: We hear “sound bites” saying ‘DON’T USE THIS IN CANCER PATIENTS’, or ‘THIS IS DANGEROUS’ etc. and are often confused. It becomes more confusing when the ‘experts’ will not all agree, and the treating physician …
#53 Assessment Part-4 Interrelationships in Chronic Disease CE 1.5 Total | 0.5 of which are Pharm Is it true that cancer, infections, autoimmunity and environmental disruptors all “feed on” each other? What does the science really say? If so how do we fit this into our thought process with patients? How does this inform: Prevention? …
#53 Assessment Part-4 Interrelationships in Chronic Disease Read More »
#50 HBOT-2 Neurological and Cancer Primary Considerations CE 2.0 Total | 2.0 of which are Pharm Part-2 of the HBOT series with in dpeth information regarding HBOT and cancer as well as neurological illness